BCRXBioCryst Pharmaceuticals, Inc.
Price
+11%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, undemanding price, growth steady, the market undecided.
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $218M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $78M (36% of revenue). For the full year FY2025, revenue was $875M (+94% year on year) and net income $264M. Its largest product in Q2 2026 was ORLADEYO at $158M, 72% of the disclosed total, well ahead of License Revenue And Other Income From Contract With Customer at 27%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026BioCryst Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Aug 4, 2026The Original Report otherwise remains unchanged.Exit or disposal costs (restructuring) · Form 8-K/A
- Jun 29, 2026On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”)Exit or disposal costs (restructuring) · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $219.5MThe company’s own SEC segment disclosure.
- ORLADEYO$158.2M72%
- License Revenue And Other Income From Contract With Customer$60.0M27%
- Research And Development Services$1.2M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #41 of 41 by RyuScore